ASCO25
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
ASCO25
Jun 14, 2024, 13:17 |
Blog
We are still catching our breath from ASCO24 - Realyze Intelligence
Realyze Intelligence shared on LinkedIn: " What. An. ASCO24. It's been a week and we…
Jun 7, 2024, 16:43 |
Blog
Khalid El Bairi: Ariella is one of the wonderful ASCO staff who made ASCO24 easier
Khalid El Bairi shared a post on X: "Ariella is one of the wonderful ASCO staff…
Jun 7, 2024, 00:29 |
Societies
Erika Hamilton: I am leaving ASCO24 filled with renewed energy and inspiration
Erika Hamilton shared a post on LinkedIn: "ASCO24 did not disappoint! So appreciative of Lynn…
Jun 6, 2024, 23:59 |
Societies
Jason A. Mouabbi: ASCO24 has been incredible as always!
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared on X: …
Jun 6, 2024, 00:45 |
Societies
Douglas Flora: Excited to bring back the best of ASCO24 to continue to build, Right Here
Douglas Flora recently shared a post on LinkedIn: "And it wouldn’t be ASCO without the meaningful…
Jun 5, 2024, 23:21 |
Societies
Save the date for ASCO25: May 30–June 3, 2025
Quoting the American Society of Clinical Oncology (ASCO) on LinkedIn: "Conversations sparked. Connections made. More…
Jun 4, 2024, 01:38 |
Blog
Khalid El Bairi: My first oral lecture at the Annual Meeting of the ASCO
Khalid El Bairi shared a post on LinkedIn: "Today marks my first oral lecture at the…
Jun 3, 2024, 08:16 |
Insight
Ziad Bakouny: What an incredible ASCO IMG Community of Practice session it was!
Lei Deng, Assistant Professor at University of Washington/Fred Hutchinson Cancer Centre, shared a post by…
All:
8
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube